Reporting of toxic adverse effects of anticancer treatments by clinicians generally results in the underreporting of these toxicities. Patient-reported outcomes, which fully reflect the experiences of patients receiving treatment, offer an alternative to reporting of toxicities by clinicians. In this Perspective, the authors describe the barriers and challenges to routine integration of patient-reported outcomes into clinical trials, and describe the PRO–CTCAE, which is designed to help circumvent some of these challenges.
- Massimo Di Maio
- Ethan Basch
- Francesco Perrone